|Bid||1.7200 x 999400|
|Ask||1.7350 x 1370800|
|Day's range||1.7050 - 1.7400|
|52-week range||1.5525 - 4.8300|
|Beta (5Y monthly)||1.54|
|PE ratio (TTM)||7.84|
|Earnings date||23 Aug 2022 - 29 Aug 2022|
|Forward dividend & yield||0.22 (12.68%)|
|Ex-dividend date||02 Mar 2022|
|1y target est||1.84|
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measuresEuropean Commission decision on marketing authorization application (MAA) expected in approximately 60 days If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG) Breda, the Netherlands—June 24, 2022—argenx (Eur
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
Every investor in The Liberty Braves Group ( NASDAQ:BATR.K ) should be aware of the most powerful shareholder groups...